{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:31Z","timestamp":1793689471743,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vedolizumab is an advanced therapy indicated for the treatment of moderately to severely active Crohn\u2019s disease (CD) or ulcerative colitis (UC). After induction with vedolizumab intravenous (IV), maintenance is with vedolizumab 300\u00a0mg IV every 8\u00a0weeks, or patients can transition to vedolizumab 108\u00a0mg subcutaneous (SC) every 2\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a literature review of the PubMed and Embase databases up to March 2024 to identify publications describing clinical practice experiences on the transition from vedolizumab IV to SC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 36 eligible publications were identified, comprising 4105 UC and CD patients treated with vedolizumab: 2718 with vedolizumab SC. Across studies, there was no loss of effectiveness after transition from vedolizumab IV to SC based on disease activity scores or biomarkers (C-reactive protein and fecal calprotectin). Higher vedolizumab trough levels were observed consistently with vedolizumab SC versus IV. Treatment persistence with vedolizumab SC ranged from 89.0% to 95.5% after 3\u2009\u2212\u20096\u00a0months and approximately 81% to 89% at 12\u00a0months. A willingness to transition to the SC formulation was reported by 47% to 59% of patients, due to time savings and fewer hospital visits. Patients who transitioned to vedolizumab SC showed a high level of satisfaction (75%\u2009\u2212\u200995%) with the transition. The most frequently reported adverse events with vedolizumab SC were injection site reactions, with frequencies of 2.9% to 18.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical practice experience in inflammatory bowel disease patients who transitioned from vedolizumab IV to SC showed no change in effectiveness or safety outcomes, and a high level of patient satisfaction overall.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00384-025-04966-y","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T23:25:41Z","timestamp":1755300341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical use of vedolizumab subcutaneous formulation in inflammatory bowel diseases: a review of real-world evidence"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-7277","authenticated-orcid":false,"given":"Kirk B.","family":"Russ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Agboton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Wojtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"4966_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn\u2019s disease. Lancet 389:1741\u20131755","journal-title":"Lancet"},{"key":"4966_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF (2017) Ulcerative colitis. Lancet 389:1756\u20131770","journal-title":"Lancet"},{"key":"4966_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A et al (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160:1570\u20131583","journal-title":"Gastroenterology"},{"key":"4966_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/2040622315586970","volume":"6","author":"LN Cherry","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK (2015) Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease. Ther Adv Chronic Dis 6:224\u2013233","journal-title":"Ther Adv Chronic Dis"},{"key":"4966_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-10-1","volume":"10","author":"PB Allen","year":"2010","unstructured":"Allen PB, Lindsay H, Tham TC (2010) How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 10:1","journal-title":"BMC Gastroenterol"},{"key":"4966_CR6","first-page":"412","volume":"11","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Loftus EV Jr, Colombel JF et al (2017) Long-term efficacy of vedolizumab for Crohn\u2019s disease. J Crohns Colitis 11:412\u2013424","journal-title":"J Crohns Colitis"},{"key":"4966_CR7","first-page":"154","volume":"22","author":"Y Edel","year":"2020","unstructured":"Edel Y, Sagy I, Pokroy-Shapira E et al (2020) A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. Isr Med Assoc J 22:154\u2013159","journal-title":"Isr Med Assoc J"},{"key":"4966_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S et al (2020) Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 158:562-572.e12","journal-title":"Gastroenterology"},{"key":"4966_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, D\u2019Haens G, Baert F et al (2022) Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis 16:27\u201338","journal-title":"J Crohns Colitis"},{"key":"4966_CR10","doi-asserted-by":"crossref","unstructured":"Feagan BG, Rutgeerts P, Sands BE, GEMINI 1 Study Group et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699\u2013710","DOI":"10.1056\/NEJMoa1215734"},{"key":"4966_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 369:711\u2013721","journal-title":"N Engl J Med"},{"key":"4966_CR12","unstructured":"Takeda Entyvio\u00ae (2020) Summary of product characteristics. Takeda Pharma A\/S, Denmark"},{"key":"4966_CR13","unstructured":"Takeda Vedolizumab (2020) Product monograph. Takeda Canada Inc, Toronto, ON"},{"key":"4966_CR14","unstructured":"Takeda Vedolizumab (2020) [Product information]. Takeda Pharmaceuticals Australia Pty Ltd, Sydney, Australia"},{"key":"4966_CR15","unstructured":"Takeda Entyvio\u00ae (2023) Prescribing information. Takeda Pharmaceuticals U.S.A., Inc. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761133s000lbl.pdf.\u00a0Accessed Dec 2023"},{"key":"4966_CR16","doi-asserted-by":"publisher","first-page":"i410","DOI":"10.1093\/ecco-jcc\/jjab232.551","volume":"16","author":"H Alice","year":"2022","unstructured":"Alice H, Gemma B, Selinger CP (2022) P424 Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations. J Crohn\u2019s Colitis 16:i410","journal-title":"J Crohn's Colitis"},{"key":"4966_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0927","volume":"18","author":"C Amor Costa","year":"2024","unstructured":"Amor Costa C, Garcia Ramirez L, Suarez Ferrer C et al (2024) P797 assessment of pharmacokinetics and clinical response in patients transitioning from intravenous to subcutaneous vedolizumab. J Crohns Colitis 18:i1478\u2013i1479","journal-title":"J Crohns Colitis"},{"key":"4966_CR18","first-page":"1038","volume":"11","author":"L Andr\u00e9s Pascual","year":"2023","unstructured":"Andr\u00e9s Pascual L, Arias Garc\u00eda L, Saiz CR (2023) Data in a tertiary hospital on switching from an intensified and non intensified regimen of intravenous vedolozumab to a subcutaneous in adults with inflammatory bowel disease. United European Gastroenterol J 11:1038","journal-title":"United European Gastroenterol J"},{"key":"4966_CR19","doi-asserted-by":"crossref","first-page":"i1090","DOI":"10.1093\/ecco-jcc\/jjad212.0690","volume":"18","author":"L Andr\u00e9s Pascual","year":"2024","unstructured":"Andr\u00e9s Pascual L, Arias Garc\u00eda L, Saiz Chumillas R, Chivato Mart\u00edn-Falquina I, Sicilia AB (2024) P555 Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with inflammatory bowel disease. One year follow-up J Crohns Colitis 18:i1090","journal-title":"One year follow-up J Crohns Colitis"},{"key":"4966_CR20","doi-asserted-by":"publisher","first-page":"S608","DOI":"10.1093\/ecco-jcc\/jjab074.816","volume":"15","author":"K Asnong","year":"2021","unstructured":"Asnong K, Hoefkens E, Lembrechts N, Van de Schoot I, Pouillon L, Bossuyt P (2021) N02 preview study: factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with inflammatory bowel disease. J Crohns Colitis 15:S608\u2013S609","journal-title":"J Crohns Colitis"},{"key":"4966_CR21","doi-asserted-by":"publisher","first-page":"i617","DOI":"10.1093\/ecco-jcc\/jjab232.863","volume":"16","author":"E De Dycker","year":"2022","unstructured":"De Dycker E, Hoefkens E, Asnong K et al (2022) N01 type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with inflammatory bowel disease: a multicentre, comparative study. J Crohns Colitis 16:i617\u2013i618","journal-title":"J Crohns Colitis"},{"key":"4966_CR22","first-page":"A28","volume":"72","author":"A Dhar","year":"2023","unstructured":"Dhar A, Ritchie S, Bone J, Rand V, Wake S (2023) O50 monitoring adherence to subcutaneous biologics for IBD care using digital technology \u2013 a NHSX proof of concept study following COVID-19. Gut 72:A28\u2013A29","journal-title":"Gut"},{"key":"4966_CR23","doi-asserted-by":"publisher","first-page":"i1741","DOI":"10.1093\/ecco-jcc\/jjad212.1094","volume":"18","author":"M Heijnen","year":"2024","unstructured":"Heijnen M, Straatmijer T, Maljaars J et al (2024) P964 Vedolizumab trough concentrations during subcutaneous treatment in patients with inflammatory bowel diseases. J Crohns Colitis 18:i1741\u2013i1742","journal-title":"J Crohns Colitis"},{"key":"4966_CR24","first-page":"256","volume":"10","author":"N Lamichhane","year":"2022","unstructured":"Lamichhane N, Melasn N, Bergqvistn V et al (2022) Real-world outcomes of transitioning from intravenous to subcutaneous vedolizumab treatment: a nationwide cohort based on the Swedish Inflammatory Bowel Disease Quality Register. United European Gastroenterol J 10:256\u2013257","journal-title":"United European Gastroenterol J"},{"key":"4966_CR25","volume":"70","author":"F Maw","year":"2021","unstructured":"Maw F, Chan MY, Ritchie S, Fletcher V, Dallal H, Dhar A (2021) PMO-27 switching to subcutaneous vedolizumab in inflammatory bowel disease during COVID-19 pandemic \u2013 county Durham experience. Gut 70:A91","journal-title":"Gut"},{"key":"4966_CR26","first-page":"A58","volume":"71","author":"M McLean","year":"2022","unstructured":"McLean M, Cartlidge P, Fyall J et al (2022) P43 Real-world experience of subcutaneous vedolizumab for treatment of IBD in NHS Tayside. Gut 71:A58\u2013A59","journal-title":"Gut"},{"key":"4966_CR27","unstructured":"Moser B, Schoeler L, Schirbel A, C J (2023) Efficacy and safety of swithcing from intravenous vedolizumab to subcutaneous application in patients with IBD in clinical remission. United European Gastroenterol J 11:1064"},{"key":"4966_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0939","volume":"18","author":"G Novacek","year":"2024","unstructured":"Novacek G, Hr\u00faz P, H\u00f6genauer C et al (2024) P809 variety beach: real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and Switzerland. J Crohns Colitis 18:i1506\u2013i1507","journal-title":"J Crohns Colitis"},{"key":"4966_CR29","doi-asserted-by":"publisher","first-page":"i918","DOI":"10.1093\/ecco-jcc\/jjac190.0914","volume":"17","author":"S Plachta-Danielzik","year":"2023","unstructured":"Plachta-Danielzik S, Bokemeyer B, Efken P et al (2023) P784 real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study. J Crohns Colitis 17:i918\u2013i919","journal-title":"J Crohns Colitis"},{"key":"4966_CR30","doi-asserted-by":"publisher","first-page":"i1185","DOI":"10.1093\/ecco-jcc\/jjad212.0742","volume":"18","author":"DG Ribaldone","year":"2024","unstructured":"Ribaldone DG, Parisio L, Variola A et al (2024) Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). P612 Switching from intravenous to subcutaneous VEDOlizumab formulation in ulcerative colitis patients in clinical remission: the SVEDO Study, a multicenter IG-IBD study. J Crohns Colitis. 18:i1185","journal-title":"J Crohns Colitis."},{"key":"4966_CR31","first-page":"1004","volume":"11","author":"H Schulze","year":"2023","unstructured":"Schulze H, Teich N, Stallmach A, Cavlar T, Knop J, Henneberger S (2023) Real world data in inflammatory bbowel disease on vedolizumab therapy: interim analysis of the noninterventional LISTEN II study. United Eur Gastroenterol J 11:1004","journal-title":"United Eur Gastroenterol J"},{"key":"4966_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0755","volume":"18","author":"N Teich","year":"2024","unstructured":"Teich N, Stallmach A, Schulze H, Cavlar T, Knop J, Henneberger S (2024) P625 electronic patient-reported outcomes in inflammatory bowel diseases on vedolizumab therapy: interim analysis of the non-interventional German LISTEN II study. J Crohns Colitis 18:i1201","journal-title":"J Crohns Colitis"},{"key":"4966_CR33","doi-asserted-by":"publisher","first-page":"i551","DOI":"10.1093\/ecco-jcc\/jjac190.0552","volume":"17","author":"A Todeschini","year":"2023","unstructured":"Todeschini A, Geccherle A, Signoretto P, Fasoli E, Variola A (2023) P422 transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with inflammatory bowel disease. J Crohns Colitis 17:i551\u2013i552","journal-title":"J Crohns Colitis"},{"key":"4966_CR34","doi-asserted-by":"publisher","first-page":"i1784","DOI":"10.1093\/ecco-jcc\/jjad212.1119","volume":"18","author":"B Gros","year":"2024","unstructured":"Gros B, Mance\u00f1ido Marcos N, Guardiola J et al (2024) P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU. J Crohns Colitis 18:i1784\u2013i1786","journal-title":"J Crohns Colitis"},{"key":"4966_CR35","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1093\/ecco-jcc\/jjab076.723","volume":"15","author":"J N\u00f8rgaard","year":"2021","unstructured":"N\u00f8rgaard J, Malte R, Charlotte P et al (2021) P602 Vedolizumab subcutaneous influencing disease course in Constant-care app solution. J Crohns Colitis 15:S547\u2013S548","journal-title":"J Crohns Colitis"},{"key":"4966_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020296","volume":"60","author":"\u0160 Pintar","year":"2024","unstructured":"Pintar \u0160, Han\u017eel J, Drobne D et al (2024) Remission is maintained after switch from dose-optimised intravenous treatment to subcutaneous treatment with vedolizumab in inflammatory bowel disease. Medicina (Kaunas) 60:296","journal-title":"Medicina (Kaunas)"},{"key":"4966_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/apt.16927","volume":"55","author":"V Bergqvist","year":"2022","unstructured":"Bergqvist V, Holmgren J, Klintman D, Marsal J (2022) Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther 55:1389\u20131401","journal-title":"Aliment Pharmacol Ther"},{"key":"4966_CR38","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.3390\/jcm11195669","volume":"11","author":"G Burdge","year":"2022","unstructured":"Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger CP (2022) Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations. J Clin Med 11:5669","journal-title":"J Clin Med"},{"key":"4966_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","volume":"59","author":"J Harno-Tasihin","year":"2023","unstructured":"Harno-Tasihin J, Siregar L, Paajanen M, Arkkila P, Punkkinen J (2023) Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses. Scand J Gastroenterol 59:280\u2013287","journal-title":"Scand J Gastroenterol"},{"key":"4966_CR40","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/jcm12247657","volume":"12","author":"A Kubesch","year":"2023","unstructured":"Kubesch A, Kruse N, Jungheim F et al (2023) Switching vedolizumab from IV to SC injection in inflammatory bowel disease patients with active disease: real-world experience from a German IBD cohort. J Clin Med 12:7657","journal-title":"J Clin Med"},{"key":"4966_CR41","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/ibd\/izad166","volume":"30","author":"SH Lim","year":"2023","unstructured":"Lim SH, Gros B, Sharma E et al (2023) Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: a multicenter study from the United Kingdom. Inflamm Bowel Dis 30:1284\u20131294","journal-title":"Inflamm Bowel Dis"},{"key":"4966_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020239","volume":"16","author":"V Or\u0161i\u0107 Fri\u010d","year":"2023","unstructured":"Or\u0161i\u0107 Fri\u010d V, Borzan V, \u0160ahinovi\u0107 I, Borzan A, Kurbel S (2023) Real-world study on vedolizumab serum concentration, efficacy, and safety after the transition from intravenous to subcutaneous vedolizumab in inflammatory bowel disease patients: single-center experience. Pharmaceuticals (Basel) 16:239","journal-title":"Pharmaceuticals (Basel)"},{"key":"4966_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.15403\/jgld-5084","volume":"32","author":"L Parisio","year":"2023","unstructured":"Parisio L, Settanni CR, Varca S et al (2023) Effectiveness and safety of switching from intravenous to subcutaneous vedolizumab formulation in inflammatory bowel disease patients in clinical remission. J Gastrointestin Liver Dis 32:452\u2013459","journal-title":"J Gastrointestin Liver Dis"},{"key":"4966_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.dld.2023.07.011","volume":"56","author":"DG Ribaldone","year":"2023","unstructured":"Ribaldone DG, Parisio L, Variola A et al (2023) Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: the SVEDO Study, an IG-IBD study. Dig Liver Dis 56:77\u201382","journal-title":"Dig Liver Dis"},{"key":"4966_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/ecco-jcc\/jjab224","volume":"16","author":"E Ventress","year":"2022","unstructured":"Ventress E, Young D, Rahmany S et al (2022) Transitioning from intravenous to subcutaneous Vedolizumab in patients with inflammatory bowel disease [TRAVELESS]. J Crohns Colitis 16:911\u2013921","journal-title":"J Crohns Colitis"},{"key":"4966_CR46","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.17153","volume":"56","author":"A Volkers","year":"2022","unstructured":"Volkers A, Straatmijer T, Duijvestein M et al (2022) IBD Center Amsterdam and the Dutch Initiative on Crohn and Colitis. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther 56:1044\u201354","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"4966_CR47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/00365521.2023.2176252","volume":"58","author":"TH Wiken","year":"2023","unstructured":"Wiken TH, H\u00f8ivik ML, Buer L et al (2023) Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol 58(8):863\u2013873","journal-title":"Scand J Gastroenterol"},{"key":"4966_CR48","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.3390\/jcm11247296","volume":"11","author":"C Remy","year":"2022","unstructured":"Remy C, Caron B, Gouynou C et al (2022) Inflammatory bowel disease patients\u2019 acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: the Nancy experience. J Clin Med 11:7296","journal-title":"J Clin Med"},{"key":"4966_CR49","first-page":"i1269","volume":"18","author":"P Bacsur","year":"2023","unstructured":"Bacsur P, Res\u00e1l T, Farkas B et al (2023) P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment. United European Gastroenterol J 18:i1269\u2013i1270","journal-title":"United European Gastroenterol J"},{"key":"4966_CR50","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/apt.17395","volume":"57","author":"N Richard","year":"2023","unstructured":"Richard N, Vuitton L, Fumery M (2023) Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 57:741\u2013742","journal-title":"Aliment Pharmacol Ther"},{"key":"4966_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/apt.17407","volume":"57","author":"A Volkers","year":"2023","unstructured":"Volkers A, Straatmijer T, Duijvestein M, L\u00f6wenberg M, van der Meulen A, D\u2019Haens G (2023) Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors\u2019 reply. Aliment Pharmacol Ther 57:743\u2013744","journal-title":"Aliment Pharmacol Ther"},{"key":"4966_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231166227","volume":"16","author":"Q Hu","year":"2023","unstructured":"Hu Q, Tang XZ, Liu F, Liu DW, Cao B (2023) Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis. Therap Adv Gastroenterol 16:17562848231166228","journal-title":"Therap Adv Gastroenterol"},{"key":"4966_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/17512433.2024.2318465","volume":"17","author":"G D\u2019Haens","year":"2024","unstructured":"D\u2019Haens G, Rosario M, Polhamus D et al (2024) Exposure\u2013efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn\u2019s disease and ulcerative colitis. Expert Rev Clin Pharmacol 17:403\u2013412","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4966_CR54","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1016\/j.cgh.2023.01.004","volume":"21","author":"Z Wang","year":"2023","unstructured":"Wang Z, Verstockt B, Sabino J, Ferrante M, Vermeire S, Dreesen E (2023) Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a simulation study. Clin Gastroenterol Hepatol 21:3188\u201390.e2","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4966_CR55","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1097\/MEG.0000000000002816","volume":"36","author":"S Kolehmainen","year":"2024","unstructured":"Kolehmainen S, Rautakorpi J, Loyttyniemi E et al (2024) Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 36:1193\u20131201","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4966_CR56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40261-022-01162-6","volume":"42","author":"R Alten","year":"2022","unstructured":"Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L (2022) Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater convenience and clinical benefit. Clin Drug Investig 42:477\u2013489","journal-title":"Clin Drug Investig"},{"key":"4966_CR57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/PPA.S121032","volume":"11","author":"SC Bolge","year":"2017","unstructured":"Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP (2017) Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn\u2019s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence 11:661\u2013669","journal-title":"Patient Prefer Adherence"},{"key":"4966_CR58","doi-asserted-by":"crossref","unstructured":"Scarpato S, Antivalle M, Favalli EG, RIVIERA Co-authors et al (2010) Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 49:289\u201394","DOI":"10.1093\/rheumatology\/kep354"},{"key":"4966_CR59","doi-asserted-by":"crossref","unstructured":"Richter V, Cohen DL, Kriger-Sharabi O et al (2024) Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge. J Clin Med 13","DOI":"10.3390\/jcm13051357"},{"key":"4966_CR60","first-page":"770","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner D, Rubin DT, Mease P et al (2019) Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm 25:770\u2013779","journal-title":"J Manag Care Spec Pharm"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-04966-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:02:49Z","timestamp":1786370569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-04966-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4966"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-04966-y","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"23 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"License update of Open Access to CC BY.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KBR is a consultant and has served as an advisory board member for Bristol Myers Squibb, Pfizer, and Iterative Scopes. CA, PK, and AMW are employees of and hold stock\/options in Takeda. AA is a consultant and has served as an advisory board member for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda, and has received speaker\u2019s fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"179"}}